Search

Peter T. Meinke will take the Tri-I TDI into the next phase of growth.

… Tuesday, June 12, 2018 Peter T. Meinke, PhD, an accomplished chemist with more than 30 years of industry and academic experience, has been selected to lead the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI). A pioneering academic-industry collaboration, the Tri-I TDI is designed to expedite

Memorial Sloan Kettering Cancer Center has named three investigators as recipients of this year’s Paul Marks Prize for Cancer Research.

… Monday, September 23, 2013 Memorial Sloan Kettering Cancer Center has named three investigators as recipients of this year’s Paul Marks Prize for Cancer Research . The award recognizes promising investigators aged 45 or younger for their efforts in advancing cancer research. The winners are Simon J.

… Wednesday, May 27, 2009 Goals, Milestones, and Transitions Faculty Member Stephen Nimer and First-Year Student Armine Matevossian Faculty Member Stephen Nimer and First-Year Student Armine Matevossian The goal of our graduate program is to increase the pace of translating laboratory findings into clinical

Memorial Sloan Kettering Cancer Center (MSK) and New York Cancer & Blood Specialists (NYCBS), one of the fastest-growing community oncology practices in the nation, today announced plans to open a 39,000 sq ft facility in Brooklyn, New York, in early 2023.

… Thursday, June 2, 2022 Memorial Sloan Kettering Cancer Center (MSK) and New York Cancer & Blood Specialists (NYCBS), one of the fastest-growing community oncology practices in the nation, today announced plans to open a 39,000 sq ft facility in Brooklyn, New York, in early 2023. The new facility will

Cancer immunologist Andrea Schietinger, PhD, of the Sloan Kettering Institute (SKI) at Memorial Sloan Kettering (MSK) has been honored with the prestigious National Institutes of Health (NIH) Director’s New Innovator Award. Dr. Schietinger was selected as a winner for her groundbreaking work in immune responses to cancer, molecular mechanisms underlying tumor-induced T cell dysfunction, and new approaches for cancer immunotherapy. A total of 55 New Innovator Awards were given out by the NIH this year.

… Thursday, October 5, 2017 Cancer immunologist Andrea Schietinger, PhD , of the Sloan Kettering Institute (SKI) at Memorial Sloan Kettering (MSK) has been honored with the prestigious National Institutes of Health (NIH) Director’s New Innovator Award . Dr. Schietinger was selected as a winner for her

Physician-scientists Michel Sadelain and Jedd Wolchok have been appointed to a new research team dedicated to investigating ways to harness the immune system to fight cancer.

… Wednesday, December 12, 2012 Summary Physician-scientists Michel Sadelain and Jedd Wolchok have been appointed to a new research team dedicated to investigating ways to harness the immune system to fight cancer. Michel Sadelain, Director of the Center for Cell Engineering , and Jedd Wolchok, Director

Researchers from Memorial Sloan Kettering Cancer Center (MSK) announced today that the latest results from that follicular lymphoma clinical trial have shown the three-drug combination — rituximab (Rituxan®) and lenalidomide (Revlimid®), along with epcoritamab (Epkinly®) — works better than using the two drugs alone. The findings were presented at the American Society of Hematology Annual Meeting (ASH) on December 7, 2025. The findings were also published in The Lancet.

… Sunday, December 7, 2025 Researchers from Memorial Sloan Kettering Cancer Center (MSK) announced today that the latest results from that follicular lymphoma clinical trial have shown the three-drug combination — rituximab (Rituxan ® ) and lenalidomide (Revlimid ® ), along with epcoritamab (Epkinly ®

The preliminary results of our ongoing trial investigating CAR T cell therapy to treat patients with malignant pleural disease, including mesothelioma, show “encouraging clinical outcomes”

… Thursday, May 17, 2018 The preliminary results of our ongoing trial investigating CAR T cell therapy to treat patients with malignant pleural disease show “encouraging clinical outcomes”. Currently, 12 patients people with biopsy-proven malignant pleural disease expressing mesothelin (MSLN) are enrolled

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments.

… Friday, June 2, 2023 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: John Maciejowski Awarded the 2023 Pershing Square Sohn Prize for Young Investigators in Cancer Research John Maciejowski Awarded the 2023 Pershing Square Sohn Prize for Young Investigators

Scientists at the Sloan Kettering Institute have identified a fundamentally new type of protein-sorting system in cells.

… Monday, August 12, 2019 Summary Researchers at the Sloan Kettering Institute have made a fundamental discovery about how proteins are transported to the right location inside cells.  One of the most significant scientific milestones of the 20th century was cell biologist Günter Blobel’s discovery of